ClinicalTrials.gg
Active, not recruitingNCT07352969Updated Sep 22, 2026

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

A Phase 2 interventional study of IBI3016 and Placebo in Hypertension, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Enrollment
112th of 306
352 · median 255
Started
2026
with 36 others
Phase 2
14 of 408
5 open now
Primary completion
2029-03
later than 130 of 145 live
Registered
367th of 408
by date

Among the 408 studies in Hypertension with a site in China, this one is the 112th largest by enrollment of the 306 interventional ones that give a count, is one of 37 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 130 of the 145 other live ones, and was the 367th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Read the detailed description

Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Males or females aged 18 to 75 years.
  3. Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
  4. Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM.
  5. Participants able to understand and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known history of secondary hypertension.
  2. Orthostatic hypotension.
  3. Laboratory parameter assessments outside of range at screening:

    • (ALT) or Aspartate Aminotransferase (AST) > 2× (ULN)
    • Total > 1.5× ULN
    • (INR) > 2.0
    • Serum Potassium > 5 mg/L
    • Estimated (eGFR) ≤ 45 mL/min/1.73m²
    • > 480 ms
  4. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
  5. Current or history of intolerance to ACEi and/or ARBs.
  6. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, , or cardiac arrhythmias within 6 months prior to screening. Any history of congestive heart failure.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    IBI3016 dose 4

    subcutaneous injection

    Drug: IBI3016

  • Experimental
    IBI3016 dose 1

    subcutaneous injection

    Drug: IBI3016

  • Experimental
    IBI3016 dose 2

    subcutaneous injection

    Drug: IBI3016

  • Placebo comparator
    placebo

    subcutaneous injection

    Other: Placebo

  • Experimental
    IBI3016 dose 3

    subcutaneous injection

    Drug: IBI3016

  • Experimental
    IBI3016 dose 5

    subcutaneous injection

    Drug: IBI3016

Interventions

  • Solution of Injection

  • OtherPlacebo

    0.9% sodium chloride saline solution

06

What researchers measure

Primary outcomes

  1. Change in SBP by OBPM

    Change from baseline at Month 3 in systolic blood pressure (SBP) by office blood pressure measurement (OBPM)

    Time frame: From baseline through month 3

Secondary outcomes

  1. Change in Mean 24hr SBP by ABPM

    Change from baseline at Month 3 in mean 24hr SBP by ambulatory blood pressure measurement (ABPM)

    Time frame: From baseline through month 3

  2. Change in SBP and DBP by OBPM

    Change from baseline through month 6 in SBP and diastolic blood pressure (DBP) by OBPM

    Time frame: From baseline through month 6

  3. Change in Mean 24hr, mean daytime, mean nighttime SBP and DBP by ABPM

    From baseline through month 6

    Time frame: Change from baseline through month 6 in Mean 24hr, mean daytime, mean nighttime SBP and DBP by OBPM

  4. Percentage Change in AGT by blood test

    Percentage Change from baseline through month 24 in Angiotensinogen (AGT) by blood test

    Time frame: From baseline through month 24

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 37 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 20, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Mar 27, 2029
CompletionEst.
Mar 27, 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07352969
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Feb 5, 2026
Primary completion
Mar 27, 2029 (estimated)
Completion
Mar 27, 2029 (estimated)
Last update
Sep 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3016

Start the discussion